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Background: Well-established influenza surveillance 
systems (ISS) can be used for respiratory syncytial 
virus (RSV) surveillance. In Portugal, RSV cases are 
detected through the ISS using the European Union 
(EU) influenza-like illness (ILI) case definition. Aim: 
To investigate clinical predictors for RSV infection and 
how three case definitions (EU ILI, a modified EU acute 
respiratory infection, and one respiratory symptom) 
performed in detecting RSV infections in Portugal. 
Methods: This observational retrospective study used 
epidemiological and laboratory surveillance data 
(October 2010–May 2018). Associations between clini-
cal characteristics and RSV detection were analysed 
using logistic regression. Accuracy of case definitions 
was assessed through sensitivity, specificity, and 
area under the receiver operating characteristic curve 
(AUC). A 0.05 significance level was accepted. Results: 
The study involved 6,523 persons, including 190 (2.9%) 
RSV cases. Among 183 cases with age information, RSV 
infection was significantly more frequent among indi-
viduals < 5 years (n = 23; 12.6%) and ≥ 65 years (n = 45; 
24.6%) compared with other age groups (p < 0.0001). 
Cough (odds ratio (OR): 2.4; 95% confidence interval 
(CI): 1.2–6.5) was the best RSV-infection predictor 
considering all age groups, while shortness of breath 
was particularly associated with RSV-positivity among 
≤ 14 year olds (OR: 6.7; 95% CI: 2.6–17.4 for 0–4 year 
olds and OR: 6.7; 95% CI: 1.5–28.8 for 5–14 year olds). 
Systemic symptoms were significantly associated with 
RSV-negative and influenza-positive cases. None of 
the case definitions were suitable to detect RSV infec-
tions (AUC = 0.51). Conclusion: To avoid underestimat-
ing the RSV disease burden, RSV surveillance within 
the Portuguese sentinel ISS would require a more 
sensitive case definition than ILI and, even a different 
case definition according to age.
Introduction
The human respiratory syncytial virus (RSV) is a major 
cause of morbidity and mortality worldwide since it 
is the predominant viral agent affecting the respira-
tory tract, causing acute, sometimes fatal lower res-
piratory tract infections in infants, young children and 
the elderly [1]. In fact, RSV has been associated with 
a substantial disease burden in adults, especially in 
the elderly, with an estimation of 1.5 million episodes 
of acute respiratory infection (ARI) in industrialised 
countries in 2015 [2-4]. Moreover, according to a study 
in the same year, the global burden of RSV-associated 
acute lower respiratory infection has been estimated at 
33.1 million annually resulting in over 3.2 million severe 
illness that required hospitalisation in children younger 
than 5 years [5].
Currently, the available options for clinical manage-
ment of RSV disease are symptomatic supportive care 
[6] as well as Palivizumab. Palivizumab is a humanised 
antibody against the F glycoprotein of the virus. It pre-
vents RSV infection and has been shown to reduce the 
number of hospitalised cases by half [7]. It can also be 
employed to treat RSV but it does not reduce RSV mor-
tality and its use is limited to selected populations in 
high-resource settings [6,8-10]. Several RSV vaccines 
are progressing in phase III clinical trials and RSV vac-
cines are expected to become available in the coming 5 
to 10 years. With this perspective, evidence-based sup-
port for vaccination policies at the national, regional 
and global levels is necessary and, in 2015, the World 
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Health Organization (WHO) made it a high priority 
to establish robust age-specific estimates of those 
affected by RSV and globally-compatible RSV-disease-
burden surveillance systems [11]. Many countries how-
ever detect RSV infections within existing surveillance 
systems for influenza [12-13]. Moreover, one of the 
challenges to implement a global RSV surveillance sys-
tem is the lack of a uniform case definition. Influenza 
case definitions may be less sensitive for RSV and, 
consequently, have the potential to underestimate the 
RSV burden [14]. Indeed, a broader ARI case defini-
tion, which includes a sudden onset of symptoms and 
at least one respiratory symptom (cough, sore throat, 
shortness of breath or coryza), has been considered to 
be more suitable for capturing RSV infections [1,15].
In Portugal, RSV cases are detected using the standard 
European Union (EU) influenza-like illness (ILI) case 
definition through the influenza surveillance system 
(ISS). The EU ILI case definition includes sudden onset 
of symptoms, at least one respiratory symptom (cough, 
sore throat, shortness of breath), and at least one sys-
temic symptom (fever or feverishness, malaise, head-
ache or myalgia) [15]. Therefore, we aimed to evaluate 
signs and symptoms as clinical predictors of RSV, and 
to estimate the sensitivity and specificity of three case 
definitions, including EU ILI, a modified EU ARI [15], 
and one respiratory symptom, for detecting RSV infec-
tions through the country’s sentinel ISS.
Methods
Portuguese Influenza Surveillance System
The Portuguese ISS comprises a sentinel and a non-
sentinel component. The sentinel component, which 
is the sentinel ISS, exists since 1990 and is composed 
by the General Practitioners’ (GP) Sentinel Network, 
GP from the I-MOVE’s Euro EVA project (which is a pro-
ject to monitor the effectiveness of influenza vaccine 
in the EU at a community-level) and the Emergency 
and Obstetric Departments Networks. The sentinel 
ISS includes primary healthcare centres, general hos-
pitals with paediatric and adult emergency rooms and 
medical wards, and one reference paediatric hospital 
in Lisbon. Age and sex distribution of the population 
under observation in the GP Sentinel Network is simi-
lar to that of the Portuguese population [16]. Using a 
data reporting form, the sentinel ISS weekly reports 
demographic, clinical and laboratory data of individu-
als tested for influenza and other respiratory viruses 
to the National Reference Laboratory for Influenza and 
other Respiratory Viruses at the National Institute of 
Health Doutor Ricardo Jorge (INSA) during the influenza 
season. The influenza season comprises the period 
between week 40 (October) and week 20 (May) of the 
next year. In addition, the sentinel ISS sends naso-
pharyngeal swabs for influenza and other respiratory 
viruses diagnosis to INSA.
The non-sentinel component of the ISS is formed by the 
Portuguese Laboratory Network for the Diagnosis of 
Influenza Infection (PLNDII), which comprises 14 hos-
pital-based laboratories and is coordinated by INSA. 
The PLNDII was established in 2009 in response to the 
influenza pandemic to monitor trends in influenza and 
other respiratory viruses, including adenovirus, entero-
virus D68, human coronavirus, human metapneumovi-
rus, parainfluenza (1, 2 and 3), rhinovirus, and RSV A 
and B. It reports to INSA the same data as the sentinel 
ISS with the exception of clinical characteristics.
Study population and data
Individuals tested through the sentinel ISS from 2010 
to 2018 in Portugal for any respiratory virus (adeno-
virus, enterovirus D68, human coronavirus, human 
metapneumovirus, parainfluenza (1, 2 and 3), rhinovi-
rus and RSV A and B) with epidemiological, clinical and 
laboratory data were included in the study. Data were 
collected based on the detection of influenza cases 
through the sentinel ISS using the EU ILI case defini-
tion. Clinical characteristics were interpreted by the 
doctors or reported by the patients (or their parents if 
Table 1
Case definitions tested for accuracy of respiratory syncytial virus detection through the sentinel influenza surveillance 
system, Portugal, 2010–2018
Case definition Sudden onset of symptoms Respiratory symptoms Systemic symptoms
ILI 
 
(EU, 2012)
Yes At least one among: cough, sore throat or shortness of breath
At least one among: fever or 
feverishness, malaise, headache, 
myalgia
ARI-likea 
 
(EU, 2012)
Yes At least one among: cough, sore throat or shortness of breath No
One respiratory symptom No At least one among: cough, sore throat or shortness of breath No
ARI: acute respiratory infection; EU: European Union; ILI: influenza-like illness.
a The EU case definition for ARI includes coryza in the group of respiratory symptoms, as well as the clinician’s judgement that the illness is 
due to an infection. In this study, coryza and the clinician’s judgement were not included in the ARI-like case definition because they were 
not collected in the Portuguese Influenza Surveillance System.
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the children could not). Missing characteristics were 
indicated as unknown or not reported. Persons were 
excluded from the study if they had the following miss-
ing clinical characteristics: sudden onset of symptoms 
or ≥ 2 respiratory symptoms or ≥ 2 systemic symptoms. 
RSV detection was performed using real-time PCR as 
previously described by Gunson et al. [17], with a slight 
modification of cycling conditions (30 min at 50 °C, 
2 min at 95 °C, followed by 45 cycles at 95 °C for 8 s and 
60 °C for 1 min).
Ethical statement
Data used within this study were anonymised and were 
collected: (i) in the scope of epidemiological surveil-
lance for which submission to an ethical committee 
is not required and (ii) specific projects including GP 
Sentinel Network and I-MOVE’s Euro EVA, which had 
already been approved by the Health Ethic Committee 
of INSA.
Case definitions tested
The EU ILI case definition is used in the sentinel 
ISS. However, not all individuals fulfilled its criteria. 
Therefore, in order to validate the accuracy of RSV 
detection through the ISS, we decided to test three dif-
ferent case definitions (Table 1): (i) EU ILI, (ii) a modi-
fied EU case definition for ARI (ARI-like), and (iii) only 
one respiratory symptom of the three included in ARI-
like/ILI case definitions. ARI-like and only one respira-
tory symptom case definitions were created based on 
the clinical characteristics that were reported by the 
sentinel ISS.
Data analysis
Retrospective analyses were performed on data 
from individuals included in the study. Demographic 
characteristics were described using percentages. 
Associations were assessed using the chi-squared 
test. For the sudden onset of symptoms, each symp-
tom and the three case definitions, we calculated the 
odds ratios (OR) and 95% confidence intervals (CI) to 
evaluate their association with laboratory-confirmed 
RSV by bivariate logistic regression. Moreover, we cal-
culated the relative risk ratio (RRR) and 95% CI for labo-
ratory-confirmed RSV and influenza using multinomial 
analysis for three groups: (i) RSV-positive cases, (ii) 
influenza-positive cases and (iii) a reference group that 
included negative cases for any respiratory virus. Case 
definition performance characteristics, including sensi-
tivity, specificity, and area under the receiver operator 
characteristic curve (AUC), were evaluated according to 
the age group [18]. Tests with p value < 0.05 were con-
sidered statistically significant. The data analysis was 
performed using STATA 12.
Results
Selection of study patients and demographic 
characteristics
During the influenza seasons between 2010 and 
2018, 7,085 individuals were tested for any respira-
tory viral agent (Figure). Of these, 562 were excluded 
from this study due to missing clinical characteris-
tics. Remarkably, myalgia and malaise were miss-
ing in children aged ≤ 14 years. Data on age were not 
recorded for 97 individuals. For the 6,426 persons with 
known age, the majority were 15–64 years old (73.0%; 
n = 4,689), followed by ≥ 65 years old (14.9%; n = 961), 
5–14 years old (9.3%; n = 596), and < 5 years old (2.8%; 
n = 180). The female–male ratio was 1.36:1. Among the 
6,523 patients included in the study, 66.3% (n = 4,322) 
were laboratory-confirmed for any respiratory virus 
and a significant (p < 0.0001) difference was found 
according to the age group. Observed frequencies were 
higher than those ones expected if respiratory virus 
infection and age were independent among children 
aged < 5 years (154.0 vs 118.9) and 5–14 years (444.0 vs 
393.8) (data not shown). Moreover, 5,142 (78.9%) and 
5,162 (79.1%) fulfilled the ILI and ARI-like case defini-
tions, respectively.
 
Among RSV-positive cases the female–male ratio 
seemed to be higher (1.85:1) than among negative 
counterparts (1.37:1) (Table 2). Most of RSV-positive 
cases (58.5%; 107/183) were adults between 15 
and 64 years old. However, observed frequencies of 
RSV infection were statistically significantly higher 
(p < 0.0001) in children aged < 5 years (12.6%; 23/183) 
and adults ≥ 65 years (24.6%; 45/183) in comparison 
with other age groups.
Figure 
Respiratory virus surveillance data obtained through the 
sentinel influenza surveillance system, Portugal, 2010–
2018 (n = 7,085 individuals)
7,085 individuals were tested for any 
respiratory virus
562 individuals were excluded
6,523 subjects were included in the study:
5,142 (78.9%) fulfilled ILI case definition
5,162 (79.1%) fulfiled ARI-like case definition
Winter seasons between 
2010−2018a
RSV only
190 (2.9%)
Influenza only
3,093 (47.4%)
Multiple viruses
68 (1.0%)
Other viruses
971 (14.9%)
No viruses
2,201 (33.7%)
ARI: acute respiratory infection; ILI: influenza-like illness; RSV: 
respiratory syncytial virus.
a The sampling method differed depending on the season, but 
no significant difference in RSV prevalence in function of the 
season was found.
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Clinical predictors of respiratory syncytial 
virus infection
The most predictive clinical symptoms for laboratory-
confirmed RSV were cough (OR: 2.4; 95% CI: 1.2–6.5) 
and shortness of breath (OR: 2.1; 95% CI: 1.6–2.9), 
whereas fever or feverishness (OR: 0.4; 95% CI: 0.3–
0.6), headache (OR: 0.7; 95% CI: 0.5–0.9) and myalgia 
(OR: 0.4; 95% CI: 0.3–0.5) were negatively associated 
with RVS-positive cases (Table 3). When we strati-
fied by age groups, the clinical predictors for RSV-
positive cases differed according to the age group. 
Adults ≥ 65 years old did not show any significant clini-
cal predictor. Shortness of breath was more likely in 
RSV-positive than in RSV-negative cases aged ≤ 14 years 
(OR: 6.7 for 0–4 year olds; OR: 6.7 for 5–14 year olds). 
Finally, the ILI (OR: 2.5; 95% CI: 1.3–4.9) and ARI-like 
(OR: 2.5; 95% CI: 1.3–4.8) case definitions were only 
significantly associated with RSV-positive cases in 
15–64 year olds.
Multinomial analysis showed that cough (RRR: 4.1; 
95% CI: 2.1–8.1) and shortness of breath (RRR: 1.8; 
95% CI: 1.3–2.5) were significantly associated 
(p < 0.0001) with RSV-positive cases whereas fever or 
feverishness (RRR: 0.6; 95% CI: 0.4–0.8) and myalgia 
(RRR: 0.5; 95% CI: 0.3–0.7) were negatively associ-
ated (Table 4). With the exception of malaise and sore 
throat, which were not significant, and shortness of 
breath (RRR: 0.7; 95% CI: 0.6–0.8), all clinical charac-
teristics, including the EU ILI, the ARI-like and the one 
respiratory symptom case definitions, were signifi-
cantly associated with influenza-positive cases.
Performance of the influenza-like illness, acute 
respiratory infection-like and one respiratory 
symptom case definitions
When testing the performance of the case definitions, 
one respiratory symptom had the highest sensitivity 
for detection of RSV with 99.5%, whereas the ILI and 
ARI-like case definitions revealed the highest specifici-
ties with 21.1% and 20.8%, respectively (Table 5). AUC 
was 0.51 in all case definitions.
Concerning the analysis by age group, for children 
< 5 years old the ILI and ARI-like case definitions pre-
sented the lowest sensitivity (56.5%) and the highest 
specificity (27.7% and 26.4%, respectively). Only one 
respiratory symptom as case definition showed the 
highest sensitivity (100%) in all age groups, with the 
exception of the 5–14 years’ age group. This definition 
had the lowest specificity with a range from 2.5% to 
3.3% depending on the age group. The ILI and ARI-
like case definitions presented the highest AUC in the 
15–64 years’ age group (0.56 for both definitions) and 
the lowest in the children < 5 years old (0.42 for ILI and 
0.41 for ARI-like).
Discussion
Although many studies regarding RSV have focused on 
children aged under 5 years and elderly adults, little is 
known regarding RSV among patients of all ages. This 
study evaluated the clinical characteristics and the 
performance of three different case definitions for the 
diagnosis of RSV infection based on epidemiological 
and laboratory data from 2010 to 2018 in Portugal.
In comparison with other age groups, laboratory-con-
firmed respiratory infection frequency in children aged 
Table 2
Demographic characteristics of individuals detected positive and negative for respiratory syncytial virus, who were tested 
through the sentinel influenza surveillance system, Portugal, 2010–2018 (n = 6,455 persons)a
Demographic characteristicsb
Virus infectiona
RSV-positive cases RSV-negative cases
n % n %
Age group in years
0–4c (n = 171) 23 12.6 148 2.4
5–14 (n = 585) 8 4.4 577 9.3
15–64 (n = 4,652) 107 58.5 4,545 73.6
≥ 65c (n = 951) 45 24.6 906 14.7
Total (n = 6,359) 183 100.0 6,176 100.0
Sex
Male (n = 2,698) 66 35.1 2,632 42.1
Female (n = 3,736) 122 64.9 3,614 57.9
Total (n = 6,434) 188 100.0 6,246 100.0
RSV: Respiratory syncytial virus.
a Of 6,523 individuals included in the study, those with mixed infections (n = 68) were excluded in this Table.
b Cases with missing age or sex were excluded from the analyses by age or sex respectively. Age was missing for seven RSV-positive and 89 
RSV-negative cases; sex was missing for two RSV-positive and 19 RSV-negative cases.
c Observed frequencies were higher than expected among these age groups: 0–4 and ≥ 65 years (p < 0.0001).
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Table 4
Comparison of clinical characteristics of respiratory syncytial virus-positive and influenza-positive groups with a group 
negative for any respiratory virus using multinomial analysis, Portugal, 2010–2018 (n = 5,484 persons)
Clinical characteristics
Viral respiratory infectiona
RSV Influenza
RRR 95% CI p value RRR 95% CI p value
Sudden onset of symptoms 1.2 0.8–1.8 0.361 1.2 1.08–1.43 0.002
Symptoms
Fever or feverishness 0.6 0.4–0.8 0.002 3.3 2.7–4.1 < 0.0001
Malaise 0.7 0.4–1.19 0.114 1.2 1.0–1.5 0.036
Headache 0.8 0.6–1.1 0.265 1.6 1.4–1.8 < 0.0001
Myalgia 0.5 0.3–0.7 < 0.0001 1.7 1.4–2.0 < 0.0001
Cough 4.1 2.1–8.1 < 0.0001 3.6 3–4.4 < 0.0001
Sore throat 1.3 0.9–1.9 0.112 1.1 1–1.3 0.108
Shortness of breath 1.8 1.3–2.5 < 0.0001 0.7 0.6–0.8 < 0.0001
Case definition
ILI 1.4 1.0–2.1 0.063 1.5 1.3–1.7 < 0.0001
ARI-like 1.5 1.0–2.2 0.044 1.4 1.3–1.6 < 0.0001
One respiratory symptom 10.1 1.4–73 0.022 2.8 2.0–3.9 < 0.0001
ARI: acute respiratory infection; CI: confidence interval; ILI: influenza-like illness; RRR: relative risk ratio; RSV: respiratory syncytial virus.
a Comparison with the reference group, which comprises individuals testing negative for any respiratory virus.
All persons were detected through the Portuguese sentinel Influenza Surveillance System.
Table 5
Sensitivity, specificity and area under the curve of the tested case definitions for detection of respiratory syncytial virus 
through the sentinel influenza surveillance system, by age, Portugal, 2010–2018 (n =6,455 persons)
Age in years
EU ILI 
 
% (95% CI)
ARI-like 
 
% (95% CI)
One respiratory symptom 
 
% (95% CI)
Sensitivity
   0–4 56.5 (34.5–76.8) 56.5 (34.5–76.8) 100 (85.2–100)
   5–14 87.5 (47.3–99.7) 87.5 (47.3–99.7) 87.5 (47.3–99.7)
   15–64 90.7 (83.5–95.4) 90.7 (83.5–95.4) 100 (96.6–100)
   ≥ 65 75.6 (60.5–87.1) 75.6 (60.5–87.1) 100 (92.1–100)
   Total 81.1 (74.7–86.4) 82.1 (75.9–87.3) 99.5 (97.1–100)
Specificity
   0–4 27.7 (20.7–35.7) 26.4 (19.5–34.2) 2.7 (0.7–6.8)
   5–14 19.2 (16.1–22.7) 19.1 (15.9–22.5) 3.3 (2.8–3.8)
   15–64 20.7 (19.5–21.9) 20.5 (19.4–21.7) 3.3 (2.8–3.8)
   ≥ 65 23.8 (21.1–26.8) 23.1 (20.4–26) 2.5 (1.6–3.8)
   Total 21.1 (20.1–22.1) 20.8 (19.8–21.9) 3.1 (2.7–3.6)
AUC
   0–4 0.42 (0.31–0.53) 0.41 (0.30–0.52) 0.51 (0.50–0.53)
   5–14 0.53 (0.41–0.66) 0.53 (0.41–0.66) 0.45 (0.33–0.58)
   15–64 0.56 (0.53–0.59) 0.56 (0.53–0.58) 0.52 (0.51–0.52)
   ≥ 65 0.50 (0.43–0.56) 0.49 (0.43–0.56) 0.51 (0.51–0.52)
   Total 0.51 (0.48–0.54) 0.51 (0.49–0.54) 0.51 (0.51–0.52)
ARI: acute respiratory infection; AUC: area under curve; CI: confidence interval; EU: European Union; ILI: influenza-like illness.
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≤ 14 years was significantly higher than what would 
be expected if respiratory virus infection and age 
were independent. Moreover, RSV infection was sig-
nificantly associated with two age groups, 0–5 years 
and ≥ 65 years, which is consistent with RSV infection 
being considered as one of the most common causes 
of respiratory tract infection during childhood as well 
as among elderly adults or adults with underlying med-
ical conditions [19].
The clinical characteristics associated with RSV-
positive cases varied across age groups, which sug-
gested that a different case definition according to age 
might be suitable. Among respiratory symptoms, short-
ness of breath was significantly associated with being 
RSV-positive among children aged ≤ 14 years, whereas 
cough was most common (94.7%) and significantly 
associated with RSV infection overall. Nonetheless, 
no significant difference in the frequency of cough, 
either positive or negative, was found between age 
groups when we stratified by age, which differed from 
previous studies that found cough associated with 
RSV infection in children under 5 years old [12,20-22]. 
Among the systemic symptoms, fever has always been 
controversial as to its inclusion in the case definition 
for RSV infection [23]. In our study, fever or feverish-
ness was very frequently observed among RSV-positive 
cases ≤ 14 years old (95.7–100%). However, no signifi-
cant difference between this age group and others, 
either positive or negative, was found, which was in 
agreement with Nyawanda et al. [12] but not with other 
studies [14,20,21]. Moreover, among the 15–64 and ≥ 
65 year olds, the observed frequencies (53.3–65.4%) 
of this symptom were similar to previous studies con-
ducted in adults [24,25] and negatively associated with 
RSV-positive cases.
Overall in the current study, good clinical predictors for 
laboratory-confirmed RSV infection were respiratory 
symptoms including cough and shortness of breath 
whereas systemic symptoms were negatively associ-
ated. These findings were also in agreement with the 
results from the multinomial analysis. In this analy-
sis, taking respectively as a reference persons testing 
negative for any respiratory virus, several considerable 
differences were found in the presentation of influenza 
and RSV, with all clinical characteristics considered in 
the EU ILI case definition significantly associated with 
influenza-positive cases with the exception of malaise, 
sore throat and shortness of breath. Therefore, it may 
be easier to diagnose influenza than RSV infection 
based on the considered clinical characteristics and 
case definitions in this study.
Much of what is known about RSV globally comes 
from surveillance systems that use case definitions 
intended for influenza, which are not optimised for 
RSV detection. In our study, we demonstrated that the 
EU ILI case definition, which is the one used in the 
current Portuguese sentinel ISS, was not accurate for 
RSV detection, and in fact, it was only a good clinical 
predictor in the 15–64 years’ age group. Furthermore, 
none of the evaluated three case definitions was able 
to discriminate among RSV-positive and negative 
cases with sufficiently high sensitivity and specificity 
to be clinically reliable because all these definitions 
presented an AUC of 0.51. However, the optimal case 
definition should be determined considering the epide-
miological context, available resources, study popula-
tion and the objective for which it is being used. Only 
one respiratory symptom showed the highest sensi-
tivity with 99.5%, which may be very good to better 
understand burden, seasonality and mortality associ-
ated with RSV infection. In fact, a very high proportion 
of hospitalisations are due to respiratory symptoms 
[21]. For vaccine effectiveness studies, a highly specific 
case definition would be more suitable [26,27] and the 
ILI and ARI-like case definitions showed higher specifi-
cities (21.1% and 20.8%, respectively) than only one 
respiratory symptom, albeit they were low in compari-
son with previous studies in hospitalised children [12].
In interpreting our results, the following limitations 
should be taken into consideration. Firstly, miss-
ing symptoms of myalgia and malaise were mostly 
among individuals aged under 14 years. Secondly, the 
number of persons of this age group was very low in 
comparison with other age groups, with only 21 chil-
dren under 1 year old included in the study, thus not 
allowing further age-stratified analyses in the 0−14 
year-old age group. Thirdly, the analysis did not dif-
ferentiate between inpatients and outpatients and, 
indeed, most collected information was from outpa-
tients, whose underlying risk factors were unknown. 
Finally, data were collected based on EU ILI case defi-
nition and thereby, individuals presenting only one res-
piratory symptom might have not been selected to test 
for any respiratory virus resulting in a selection bias. 
Therefore, these findings may not be representative for 
inpatient respiratory disease surveillance and the most 
severe spectrum of cases with RSV infection. However, 
we believe that this study may contribute to decide the 
best option for RSV surveillance in Portugal, especially 
at a community level, and may help support public 
health strategies and interventions at a European and 
global level regarding the prophylaxis and treatment 
options.
In Portugal, the most feasible option would be to 
include RSV surveillance within the existing sentinel 
ISS. We demonstrated that the current EU ILI case defi-
nition was not suitable to detect RSV infections and 
indeed, a more sensitive case definition to avoid the 
underestimation of RSV burden disease and a different 
case definition according to age would be more appro-
priate. Moreover, hospital-based surveillance, espe-
cially with a focus on paediatric patients, including 
paediatric intensive care units, should be specifically 
enhanced for RSV.
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